Sitagliptin Addition to Liraglutide/Metformin Investigated for Improved Glycemic Control in T2D
Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D
Abstract
A study aimed to quantify differences in glycemic control and incretin secretion when sitagliptin or placebo was added to pre-existing liraglutide and metformin therapy in T2D patients.